Oxalisin (Oxaliplatin)

Oxaliplatin, the active ingredient in Oxalisin, is a platinum-based chemotherapy agent presented as a unknown strength/unknown form for epidural, intrabursal and intracoronary use. It treats various solid tumours, particularly colorectal cancer, in adult oncology patients.

GNH USA supplies Oxalisin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Oxaliplatin is employed within the platinum‑based chemotherapy class for the treatment of several solid tumours.

- Colorectal cancer: improves the overall response rate when used with 5‑FU/LV. - Gastric cancer: used as part of combination regimens to enhance tumour shrinkage. - Pancreatic disease (adenocarcinoma): contributes to tumour control by DNA damage induction of the cancer cells. - Ovarian cancer : provides additional cytotoxic activity in platinum‑sensitive regimens of the patient ‑    -   

Oxaliplatin may exhibit several adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and the   -   -  -  -  - 

Serious or Rare Side Effects: -   -  -  -  - 

Oxaliplatin requires careful clinical monitoring and patient assessment before and during therapy.

- Renal function: assess   -   -  -  -  - Store at 25 ");

  """"  " " " " "" "" """ """ " "" " """" " ""